St. Jude Research
@stjuderesearch.bsky.social
St. Jude Children's Research Hospital: a leader in research and treatment of pediatric cancer and childhood diseases.
Scientists at St. Jude and Northwestern University have uncovered how CRISPR-Cas9 gene therapy silences BCL11A in sickle cell disease and β-thalassemia. The therapy disrupts a 3D genome structure essential for BCL11A expression, reactivating fetal hemoglobin. ow.ly/to6w50XpI9H
Gene therapy for sickle cell and β-thalassemia works by disrupting three-dimensional genome structure
See how scientists identified a previously unknown treatment opportunity for sickle cell disease and β-thalassemia based on how CRISPR-based gene therapy works
ow.ly
November 10, 2025 at 10:06 PM
Scientists at St. Jude and Northwestern University have uncovered how CRISPR-Cas9 gene therapy silences BCL11A in sickle cell disease and β-thalassemia. The therapy disrupts a 3D genome structure essential for BCL11A expression, reactivating fetal hemoglobin. ow.ly/to6w50XpI9H
A multi-national study co-led by St. Jude analyzed 164 cases of infant-type hemispheric glioma (IHG), providing the largest dataset to date. Findings set new benchmarks for clinical decision-making in this rare, aggressive pediatric brain tumor. ow.ly/F0oR50XpvN2
Largest study on infant-type hemispheric glioma reports factors to guide treatment approaches
Largest global study of infant hemispheric glioma identifies prognostic factors to guide safer, more effective treatments.
ow.ly
November 10, 2025 at 5:46 PM
A multi-national study co-led by St. Jude analyzed 164 cases of infant-type hemispheric glioma (IHG), providing the largest dataset to date. Findings set new benchmarks for clinical decision-making in this rare, aggressive pediatric brain tumor. ow.ly/F0oR50XpvN2
Translational researchers at St. Jude are advancing pediatric cancer care by moving promising compounds from the lab to clinical trials. This process starts with identifying molecular targets for hard-to-treat childhood cancers. ow.ly/AFNa50Xo1Ez
November 7, 2025 at 3:55 PM
Translational researchers at St. Jude are advancing pediatric cancer care by moving promising compounds from the lab to clinical trials. This process starts with identifying molecular targets for hard-to-treat childhood cancers. ow.ly/AFNa50Xo1Ez
Researchers have mapped 117 kinases capable of phosphorylating the RNA polymerase II tail, revealing modifications at previously disregarded positions beyond amino acids two and five. This discovery expands our understanding of gene transcription control.
Kinase atlas uncovers hidden layers of cell signaling regulation
See how St. Jude scientists linked 117 kinases including EGFR tyrosine kinase to RNA polymerase II phosphorylation, revealing new targets for cancer therapy.
www.stjude.org
November 6, 2025 at 9:01 PM
Researchers have mapped 117 kinases capable of phosphorylating the RNA polymerase II tail, revealing modifications at previously disregarded positions beyond amino acids two and five. This discovery expands our understanding of gene transcription control.
Scientists have discovered an alternative binding pocket on the pregnane X receptor (PXR), a nuclear receptor involved in drug metabolism. This finding unlocks possibilities for drug discovery related to nuclear receptors.
Researchers find a ‘hidden pocket’ to target nuclear receptors
Discover how St. Jude scientists uncovered a hidden pocket on PXR, enabling selective PROTAC therapies for nuclear receptors.
ow.ly
November 6, 2025 at 4:16 PM
Scientists have discovered an alternative binding pocket on the pregnane X receptor (PXR), a nuclear receptor involved in drug metabolism. This finding unlocks possibilities for drug discovery related to nuclear receptors.
New research from St. Jude offers the most comprehensive analysis of medulloblastoma treatment to date, using clinical and molecular data from nearly 900 children. The findings help address the challenge of tailoring therapy to minimize long-term side-effects.
Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects
Find how St. Jude researchers discovered a new way to group patients with medulloblastoma, which could lead to major reduction in treatment-related toxicity.
www.stjude.org
November 5, 2025 at 3:02 PM
New research from St. Jude offers the most comprehensive analysis of medulloblastoma treatment to date, using clinical and molecular data from nearly 900 children. The findings help address the challenge of tailoring therapy to minimize long-term side-effects.
The Bringing Chemistry to Medicine symposium at St. Jude Children’s Research Hospital continues its remarkable growth, welcoming more than 1,000 attendees from 44 countries in 2025. Over six years, the symposium has reached over 3,000 participants from 73 countries.
November 4, 2025 at 4:34 PM
The Bringing Chemistry to Medicine symposium at St. Jude Children’s Research Hospital continues its remarkable growth, welcoming more than 1,000 attendees from 44 countries in 2025. Over six years, the symposium has reached over 3,000 participants from 73 countries.
Understanding the foundational factors affecting health—such as genetics and environment—enables more accurate prediction and prevention of disease in children. St. Jude is advancing detection and treatment to improve outcomes and quality of life.
November 3, 2025 at 7:33 PM
Understanding the foundational factors affecting health—such as genetics and environment—enables more accurate prediction and prevention of disease in children. St. Jude is advancing detection and treatment to improve outcomes and quality of life.
New research reveals how tandem duplications in the UBTF gene create an abnormal transport signal, driving a high-risk, treatment-resistant subtype of acute myeloid leukemia (UBTF-TD AML). ow.ly/aYjp50XlQmW
Abnormal transport signal on mutant UBTF gene drives high-risk acute myeloid leukemia
Learn how scientists uncovered Exportin-1 (EXPO1)’s role in UBTF-TD AML, revealing a new therapeutic target for high-risk pediatric leukemia
ow.ly
November 3, 2025 at 3:22 PM
New research reveals how tandem duplications in the UBTF gene create an abnormal transport signal, driving a high-risk, treatment-resistant subtype of acute myeloid leukemia (UBTF-TD AML). ow.ly/aYjp50XlQmW
Reposted by St. Jude Research
It's Halloween 🎃 #FlourescenceFriday! Here is a microscopic pumpkin generated by showing a cell nucleus in 🟠 with the primary cilium "stem" in 🟢! I hope everyone has a spooky 👻 day! 🔬 by @stjuderesearch.bsky.social grad student Christina Wang. 🧪
October 31, 2025 at 3:14 PM
It's Halloween 🎃 #FlourescenceFriday! Here is a microscopic pumpkin generated by showing a cell nucleus in 🟠 with the primary cilium "stem" in 🟢! I hope everyone has a spooky 👻 day! 🔬 by @stjuderesearch.bsky.social grad student Christina Wang. 🧪
Leaders at St. Jude joined experts worldwide at #SIOP2025 in Amsterdam, presenting topics ranging from advances in high-risk medulloblastoma to the future of chemotherapy-free childhood ALL treatment.
October 30, 2025 at 10:23 PM
Leaders at St. Jude joined experts worldwide at #SIOP2025 in Amsterdam, presenting topics ranging from advances in high-risk medulloblastoma to the future of chemotherapy-free childhood ALL treatment.
Scientists have engineered a modified form of florfenicol that uses the drug resistance mechanisms of Mycobacterium abscessus, which causes hard-to-treat infections due to its complex antibiotic resistance system, to activate and amplify its own antibiotic effect. ow.ly/oauk50XklPT
Approach to combat antibiotic resistance turns bacterium’s genes against it
See how scientists hack bacterial resistance to chloramphenicol to boost antibiotic power against mycobacterium abscessus, offering safer, targeted treatment
ow.ly
October 30, 2025 at 2:00 PM
Scientists have engineered a modified form of florfenicol that uses the drug resistance mechanisms of Mycobacterium abscessus, which causes hard-to-treat infections due to its complex antibiotic resistance system, to activate and amplify its own antibiotic effect. ow.ly/oauk50XklPT
Researchers identified 423 unique ultrarare genetic variants in a diverse cohort of ALS and HSP patients, revealing significant overlap in disease-linked genes previously thought to be distinct. ow.ly/x23Y50XjN3a
Common genetic causes across motor neuron diseases identified
Discover how researchers reveal shared ultrarare gene variants in ALS and HSP highlighting genetic overlap in motor neuron diseases, guiding future therapies.
ow.ly
October 29, 2025 at 3:02 PM
Researchers identified 423 unique ultrarare genetic variants in a diverse cohort of ALS and HSP patients, revealing significant overlap in disease-linked genes previously thought to be distinct. ow.ly/x23Y50XjN3a
Many pediatric neurological diseases are rare and complex, affecting only a small number of children. GEMINI was created at St. Jude to meet this challenge by identifying genetic mutations and developing targeted therapies, advancing from discovery to clinical trial.
October 28, 2025 at 2:20 PM
Many pediatric neurological diseases are rare and complex, affecting only a small number of children. GEMINI was created at St. Jude to meet this challenge by identifying genetic mutations and developing targeted therapies, advancing from discovery to clinical trial.
By generating single-cell gene expression data, St. Jude scientists discovered how metabolism regulates regulatory T cell activation during inflammation. Mitochondria and lysosome-associated pathways work together to control these immune “brakes.” ow.ly/ccxe50XhLtW
Mitochondria and lysosomes reprogram immune cells that dampen inflammation
Find how signaling between two metabolic organelles communicate to activate and deactivate regulatory T cells, with implications for immune-related disease.
ow.ly
October 24, 2025 at 6:15 PM
By generating single-cell gene expression data, St. Jude scientists discovered how metabolism regulates regulatory T cell activation during inflammation. Mitochondria and lysosome-associated pathways work together to control these immune “brakes.” ow.ly/ccxe50XhLtW
P. David Rogers, PharmD, PhD, and J. Paul Taylor, MD, PhD, have been elected to the @nam.edu, one of the highest honors in health and medicine. ow.ly/AjRy50Xf9AX
October 20, 2025 at 8:30 PM
P. David Rogers, PharmD, PhD, and J. Paul Taylor, MD, PhD, have been elected to the @nam.edu, one of the highest honors in health and medicine. ow.ly/AjRy50Xf9AX
Andrew Kleist, MD, PhD, has been named a 2025 @statnews.com Wunderkind. The designation recognizes early-career scientists making breakthrough discoveries in health and medicine. ow.ly/JEjJ50XbWhi
October 15, 2025 at 5:05 PM
Andrew Kleist, MD, PhD, has been named a 2025 @statnews.com Wunderkind. The designation recognizes early-career scientists making breakthrough discoveries in health and medicine. ow.ly/JEjJ50XbWhi
Scientists have solved the first complete structures of bacterial heat shock chaperone proteins Hsp40 and Hsp70, revealing how these proteins bind and release misfolded client proteins, a process central to cellular defense against protein aggregation. ow.ly/zaM750XboJ0
First complete structures of heat shock chaperone protein complex reveal handoff mechanism
Explore how structures of full-length heat shock protein complexes including Hsp40, Hsp70, and client proteins reveal how they work together to protect cells.
ow.ly
October 14, 2025 at 9:27 PM
Scientists have solved the first complete structures of bacterial heat shock chaperone proteins Hsp40 and Hsp70, revealing how these proteins bind and release misfolded client proteins, a process central to cellular defense against protein aggregation. ow.ly/zaM750XboJ0
St. Jude recently hosted the KIDS25 BioHackathon, an event connecting students and professionals in bioinformatics, imaging, data science, artificial intelligence and software engineering to develop solutions addressing real-world research challenges.
October 13, 2025 at 5:03 PM
St. Jude recently hosted the KIDS25 BioHackathon, an event connecting students and professionals in bioinformatics, imaging, data science, artificial intelligence and software engineering to develop solutions addressing real-world research challenges.
New findings reveal that the ASPL protein plays distinct roles in both the assembly and disassembly of stress granules—mechanisms linked to neurodegenerative diseases. ow.ly/lCP550X8H3J
Protein sidekick exhibits dual roles in stress granule assembly and disassembly
See how St. Jude researchers reveal how ASPL and VCP control stress granule assembly and disassembly, shedding light on neurodegenerative disease mechanisms.
ow.ly
October 8, 2025 at 6:02 PM
New findings reveal that the ASPL protein plays distinct roles in both the assembly and disassembly of stress granules—mechanisms linked to neurodegenerative diseases. ow.ly/lCP550X8H3J
St. Jude Children’s Research Hospital has been ranked among the top 10
pediatric cancer hospitals by U.S. News & World Report for the 18th year in a row.
Read more: ow.ly/HNLN50X7PsR
pediatric cancer hospitals by U.S. News & World Report for the 18th year in a row.
Read more: ow.ly/HNLN50X7PsR
October 7, 2025 at 2:57 PM
St. Jude Children’s Research Hospital has been ranked among the top 10
pediatric cancer hospitals by U.S. News & World Report for the 18th year in a row.
Read more: ow.ly/HNLN50X7PsR
pediatric cancer hospitals by U.S. News & World Report for the 18th year in a row.
Read more: ow.ly/HNLN50X7PsR
Proud to be ranked No. 2 on the @Forbes list of Best Employers for Healthcare Professionals! At St. Jude, we invest in our team so they can focus on our lifesaving mission.
ow.ly/HPal50X6mBj
ow.ly/HPal50X6mBj
October 3, 2025 at 6:06 PM
Proud to be ranked No. 2 on the @Forbes list of Best Employers for Healthcare Professionals! At St. Jude, we invest in our team so they can focus on our lifesaving mission.
ow.ly/HPal50X6mBj
ow.ly/HPal50X6mBj
The application deadline for the 2026 CCSS Ann C. Mertens Career Development Award has been extended through Monday, November 3.
This is a great opportunity for early-career investigators and trainees interested in childhood cancer survivorship research. Learn more: ow.ly/GOzN50WCMpP
This is a great opportunity for early-career investigators and trainees interested in childhood cancer survivorship research. Learn more: ow.ly/GOzN50WCMpP
Shape the future of childhood cancer survivorship with the 2026 CCSS Ann C. Mertens Career Development Award. This opportunity provides early-career investigators with the tools, resources and mentorship to advance survivorship research and improve outcomes.
October 3, 2025 at 1:31 PM
The application deadline for the 2026 CCSS Ann C. Mertens Career Development Award has been extended through Monday, November 3.
This is a great opportunity for early-career investigators and trainees interested in childhood cancer survivorship research. Learn more: ow.ly/GOzN50WCMpP
This is a great opportunity for early-career investigators and trainees interested in childhood cancer survivorship research. Learn more: ow.ly/GOzN50WCMpP
St. Jude researchers are advancing science by harnessing light-based technologies to explore the molecular and cellular mechanisms underlying health and disease. ow.ly/3TEI50X4nsQ
October 1, 2025 at 2:05 PM
St. Jude researchers are advancing science by harnessing light-based technologies to explore the molecular and cellular mechanisms underlying health and disease. ow.ly/3TEI50X4nsQ
At #UNGA80, St. Jude & Uzbekistan co-hosted a landmark side event, united by Bente Mikkelsen’s leadership, 8 first ladies, WHO DG @DrTedros & ministers of health worldwide. Together, we’re advancing global health for children facing catastrophic diseases.
September 30, 2025 at 3:15 PM
At #UNGA80, St. Jude & Uzbekistan co-hosted a landmark side event, united by Bente Mikkelsen’s leadership, 8 first ladies, WHO DG @DrTedros & ministers of health worldwide. Together, we’re advancing global health for children facing catastrophic diseases.